AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation...
Month: January 2023
Modern Vascular Welcomes New Managing Physician Dr. Mamdouh Khayat
Seal of Accreditation Modern Vascular is accredited by the Intersocietal Accreditation CommissionIndianapolis, IN, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Modern...
VALNEVA – Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023
VALNEVA Declaration of shares and voting rightsStatus on December 31, 2022 (corrected data) and January 4, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered...
Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital...
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with...
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023
SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated...
Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a...
Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023
NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel...
CCTV Video Captures Dramatic Rescue Following Car Crash – Heart2Heart CPR Nominates First Aid Instructor to Receive the Red Cross Rescuer Award!
TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- On Sunday December 4, 2022, Linda Hart Mulgrew, a long-standing Canadian Red Cross First...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational...
Streamline Health® Expands RevID™ Agreement with Large Provider Network, Achieves Booked SaaS ACV Goal
National Health System Expands Utilization of RevID’s Automated Charge Reconciliation for Improved Financial Performance; Company Exceeds $17M of Booked SaaS...
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients...
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused...
Dyadic Announces Sale of Equity Interest in Alphazyme
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology...
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University...
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
Sixth orphan drug designation for Nana-val globally; second granted by the European CommissionSAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) --...
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...